@24681357 The ramping appears to be just fine with some on the SPL forum .... it's the posting of negative facts that many have issues with ... lol
I still question why there was such a rush put into releasing the DEP® Irinotecan results a month out from the actual conference date in October where they are being presented when announcements like this usually get released within days (or on the actual day) of said conferences ? Delivering on something early that you didn't even declare was coming while the expected DEP® Docetaxel and Cabazitaxel results are nowhere to be seen with only 7 business days left in the month / quarter seems strange ?
Maybe as some have stated on here, it is all part of Starpharma's plan ? Who knows but expect a similar market response to these long awaited top line results for two of the three in-house DEP® phase 2 trials as last weeks DEP® Irinotecan interim results if they aren't accompanied by a license deal - just sayin'
SPL Price at posting:
16.0¢ Sentiment: None Disclosure: Held
